Sinotherapeutics (688247.SS) Stock Price

Sinotherapeutics Price

CLOSED
9.97
​
Market closed

Over the last 6 years Sinotherapeutics grew revenue by 21.5% annually, reaching 446.57 M CNY. Earnings per share have grown at 47.4% per year over the last 6 years. For Sinotherapeutics, the net margin of 10.6% is down versus 42.8% a few years ago. At today's price the dividend yield works out to roughly 0.62%. The payout ratio is around 59% of earnings.

Sinotherapeutics stock price

Access this data via the Eulerpool API

Sinotherapeutics business model & stock analysis

Sinotherapeutics, Inc. engages in the research and development, production and sales of high-end generic drugs and Contract Research Organization (CRO) services. The company is headquartered in Shanghai, Shanghai and currently employs 248 full-time employees. The company went IPO on 2022-08-25. The firm's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The firm mainly operates in the domestic market and overseas markets.

Frequently asked questions about Sinotherapeutics

Converted at the current exchange rate, the Sinotherapeutics share trades at 1.33 EUR (9.97 CNY).

The revenue cannot currently be calculated for Sinotherapeutics.

The profit cannot currently be calculated for Sinotherapeutics.

The P/E ratio cannot be calculated for Sinotherapeutics at the moment.

The P/S cannot be calculated for Sinotherapeutics currently.

The Eulerpool Quality Score for Sinotherapeutics is 2/10.

The ISIN of Sinotherapeutics is CNE100005PL9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Sinotherapeutics is 688247.SS. The ticker symbol is used to trade Sinotherapeutics shares on the stock exchange.

Fair ValueTerminal
9.27 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
1.80 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Aug 25, 2022
ISIN
CNE100005PL9
Cusip
Y8045Q105
Market capitalization
4.52 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
73.47
P/B Ratio
3.50
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
3.68 %
Dividend
Dividend yield
0.62 %
Payout Ratio
59.19 %
Dividend growth Ø5Y
—
Dividend payments per year
2
Dividend paid since
3 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Oct 10, 2026, 9:33 AM

Sinotherapeutics Peer Group

Sinotherapeutics FIGI

688247:CH · BBG0115TJCF4688247:CG · BBG0115TJDS8688247:C1 · BBG01J941KK1